NYSE · Financial Statements

Pfizer, Inc. (PFE) Revenue, Earnings & Financial Statements

$28.96 NYSE: PFE Market Cap $165.07B

Data as of Nov 16, 2026 (intraday, delayed) · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Pfizer, Inc. most recently reported annual revenue of $62.6B, net profit of $7.8B. Revenue grew at an average annual rate of 8.5% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Pfizer, Inc.: Revenue rose from $52.8B in 2016 to $62.6B in 2025, a change of +18.5% over 9 years; net profit was positive in all 10 reported years; operating margin moved from 25.9% to 27.8%, a shift of +1.9 percentage points; the most recent year shows net profit of $7.8B.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$52.8B$52.5B$40.8B$40.9B$41.7B$81.3B$101.2B$59.6B$63.6B$62.6B
Operating Expenses$39.1B$38.5B$34.1B$33.6B$32.8B$61.1B$63.1B$55.1B$48.7B$45.2B
Operating Profit$13.7B$14.1B$6.7B$7.3B$8.8B$20.2B$38.1B$4.4B$14.9B$17.4B
Operating Margin25.9%26.8%16.5%17.9%21.2%24.9%37.7%7.4%23.5%27.8%
Other Income−$5.4B−$1.8B−$3.1B$4.0B−$1.8B$4.1B−$3.4B−$3.4B−$6.9B−$9.9B
Interest$1.2B$1.3B$1.3B$1.6B$1.4B$1.3B$1.2B$2.2B$3.1B$2.7B
Depreciation$5.8B$6.3B$6.2B$5.8B$4.8B$5.2B$5.1B$6.3B$7.0B$6.6B
Profit Before Tax$8.4B$12.3B$3.6B$11.3B$7.0B$24.3B$34.7B$1.1B$8.0B$7.5B
Tax rate (%)13.4%-73.5%-7.4%5.2%5.3%7.6%9.6%-105.4%-0.3%-3.5%
Net Profit$7.2B$21.3B$11.2B$16.0B$9.2B$22.0B$31.4B$2.1B$8.0B$7.8B
EPS$1.17$3.52$1.87$2.87$1.63$3.88$5.47$0.37$1.41$1.36

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$14.2B$14.9B$13.3B$17.7B$17.8B$13.7B$14.7B$16.7B$17.6B$14.4B$15.0B$16.6B
Operating Expenses$16.2B$10.7B$11.0B$12.4B$14.6B$9.3B$10.9B$11.1B$13.9B$10.2B$11.5B$12.9B
Operating Profit−$2.0B$4.2B$2.3B$5.3B$3.2B$4.4B$3.8B$5.5B$3.7B$4.3B$3.5B$3.7B
Operating Margin-13.8%28.3%17.0%29.8%17.9%32.3%25.7%33.2%21.0%29.5%23.5%22.1%
Interest$689.0M$790.0M$778.0M$783.0M$739.0M$654.0M$654.0M$652.0M$711.0M$668.0M$667.0M$662.0M
Profit Before Tax−$4.1B$3.4B−$103.0M$4.7B−$10.0M$2.8B$3.0B$3.3B−$1.6B$3.2B−$653.0M$3.4B
Tax rate (%)19.3%8.6%130.1%5.0%4210.0%-6.8%4.6%-6.5%0.1%14.5%62.3%4.0%
Net Profit−$3.4B$3.1B$41.0M$4.5B$410.0M$3.0B$2.9B$3.5B−$1.6B$2.7B−$248.0M$3.2B
EPS−$0.60$0.55$0.00$0.78$0.07$0.52$0.51$0.62−$0.29$0.47−$0.04$0.56

Over the 10 years reported for Pfizer, Inc., borrowings increased from $41.1B in 2016 to $67.4B in 2025, cash stood at $1.1B in the latest year, shareholders' equity was $481.0M, current assets covered current liabilities 1.16 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$171.6B$171.8B$159.4B$167.5B$154.2B$181.5B$197.2B$226.5B$213.4B$208.2B
Current Assets$38.9B$41.1B$49.9B$32.8B$35.1B$59.7B$51.3B$43.3B$50.4B$42.9B
Cash$2.6B$1.3B$1.1B$1.1B$1.8B$1.9B$416.0M$2.9B$1.0B$1.1B
Inventory$6.8B$7.6B$7.5B$7.1B$8.0B$9.1B$9.0B$10.2B$10.9B$10.7B
Receivables$11.3B$11.3B$11.4B$9.5B$11.2B$15.7B$14.5B$15.5B$14.8B$15.8B
Fixed Assets$13.3B$13.9B$13.4B$13.0B$13.7B$14.9B$16.3B$18.9B$18.4B$21.5B
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$22.4B$25.7B$20.5B$28.7B$30.7B$50.7B$37.4B$25.2B$21.7B$14.2B
Other Assets$54.4B$56.0B$53.4B$48.2B$49.6B$49.2B$51.4B$67.8B$68.5B$71.3B
Total Liabilities$111.8B$100.1B$95.7B$104.1B$90.8B$104.0B$101.3B$137.2B$124.9B$121.4B
Current Liabilities$31.1B$30.4B$31.9B$37.3B$25.9B$42.7B$42.1B$47.8B$43.0B$37.0B
Borrowings$41.1B$42.6B$41.7B$50.8B$38.3B$37.0B$34.9B$70.8B$67.0B$67.4B
Other Liabilities$70.7B$57.5B$53.9B$53.3B$52.5B$67.0B$66.4B$66.4B$57.9B$54.0B
Equity$461.0M$464.0M$467.0M$468.0M$470.0M$473.0M$476.0M$478.0M$480.0M$481.0M
Reserves$59.5B$71.3B$63.4B$63.1B$63.2B$77.2B$95.7B$89.0B$88.2B$86.5B

For Pfizer, Inc., operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $9.1B; free cash flow was positive in 10 of 10 years; financing activities used $459.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$15.9B$16.5B$15.8B$12.6B$14.4B$32.6B$29.3B$8.7B$12.7B$11.7B
Investing Cash Flow−$9.8B−$7.0B$2.3B−$6.5B−$7.1B−$25.3B−$19.0B−$36.2B−$257.0M−$4.0B
Financing Cash Flow−$5.2B−$4.8B−$12.8B−$9.2B$11.5B$16.0M−$2.3B−$632.0M−$469.0M−$459.0M
Net Cash Flow−$1.0B−$1.3B−$206.0M−$50.0M$475.0M$158.0M−$1.5B$2.4B−$1.8B$99.0M
Free Cash Flow$13.9B$14.3B$13.6B$10.0B$11.6B$29.9B$26.0B$4.8B$9.8B$9.1B

Valuation & Return Ratios

MetricValue
PEG Ratio-0.70
EV / EBITDA16.86
FCF Yield7.09%
Quick Ratio1.10
Interest Coverage5.60
Return 1Y19.52%
Return 3Y19.88%
Return 5Y-23.17%

Pfizer, Inc. (PFE) financials — frequently asked questions

What is Pfizer, Inc.'s annual revenue?

Pfizer, Inc. (PFE) reported annual revenue of $62.6B in its most recent fiscal year.

What is Pfizer, Inc.'s net profit?

Pfizer, Inc. (PFE) reported net profit of $7.8B in its most recent fiscal year.

What is PFE EV/EBITDA?

Pfizer, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 16.86.

Revenue and earnings of other Drug Manufacturers - General stocks

LLY revenue $65.2BJNJ revenue $94.2BABBV revenue $61.2BMRK revenue $64.9BNVS revenue $54.8BAZN revenue $58.7BAMGN revenue $36.7BGILD revenue $29.4BNVO revenue $309.1BBMY revenue $48.2BAll Drug Manufacturers - General stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
PFE Overview PFE Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.